FATE Share Price Performance
US$1.50
-1.55 (-50.82%)
Price US$1.50
Share PriceUS$1.50
Fate Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
FATE Community Narratives
There are no narratives available yet.
Fate Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.49
- Gross Margin
- -1,260.99%
- Net Profit Margin
- -2,025.05%
- Debt/Equity Ratio
- 0%
Fate Therapeutics, Inc. Competitors
Snowflake Analysis
About FATE
- Founded
- 2007
- Employees
- 181
- CEO
- WebsiteView website
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -1.1%
- 3 Months: 6.8%
- 1 Year: 15.5%
- Year to Date: 13.8%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 1.8% in the Information Technology sector. As for the longer term, the market has actually risen by 16% in the last year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›